This webinar was recorded on Wednesday, 13th August 2025.

‍

Key Insights from the Pharma R&D Services Webinar

The pharmaceutical R&D services market is navigating a period of dynamic change. Our recent webinar explored the core trends shaping this landscape, offering a look at the challenges and opportunities through 2029.

‍

Guided by the Report’s Authors‍

Andrew Aijian and Hannah Glazier, co-authors of DeciBio’s newly released Pharma R&D Services Market Report (2024–2029), led us through the first part of the discussion, unpacking the market’s trajectory and the forces driving change. In the second half, Andrew joined Dr. Deb Phippard of Precision for Medicine for a fireside chat, diving deeper into the practical implications of these trends.

‍

Growth Tempered by Caution 

Our new report forecasts that the pharma R&D services market will grow at roughly 5% annually to reach nearly $129 billion by 2029. This is built on the fact that outsourcing has become integral to the industry, with our research showing that nearly half of all pharma R&D budgets are now spent on external partners. However, it's balanced by headwinds like geopolitical uncertainty and evolving regulations (NAMs), pushing pharma towards more flexible, cost-effective partnerships over fully outsourced models.

‍

Expert Insights from Precision for Medicine's Dr. Deb Phippard 

Our guest, Dr. Deb Phippard of Precision for Medicine, shared her on-the-ground perspective on key innovation and regulatory trends. She noted that precision medicine is rapidly expanding beyond its oncology stronghold into new areas like CNS and autoimmune diseases, powered by advances in proteomics. This expansion generates massive datasets, making AI indispensable for turning complex data into actionable discoveries—a value-add service pharma is willing to invest in. Dr. Phippard also highlighted the dual reality of global expansion and regulatory hurdles. While the Asia-Pacific region is a booming hub for clinical trials, she described the significant "existential angst" developers face from evolving FDA and IVDR demands, which is especially challenging for innovators in complex fields like gene therapy.

Ultimately, success in the coming years will belong to service providers who offer flexibility, embrace AI, and can expertly guide their partners through an increasingly complex global and regulatory landscape.

‍

Check out our webinar to hear key insights from DeciBio’s research, informed by 35 stakeholder interviews and robust financial modeling. This is a must-watch for anyone looking to better position their organization for the future of pharma services.

‍

Speakers:

• Deborah Phippard Ph.D., Chief Science Office at Precision for Medicine
• Andrew Aijian, Ph.D., Partner at DeciBio Consulting
• Hannah Glazier, Product Manager at DeciBio Consulting

Moderator:

• Megan Nacar, VP of Commercial at DeciBio Consulting

‍

Webinar Recording:

‍

‍

Our report provides a comprehensive overview of the global Pharma R&D Services market from 2024 to 2029. The market is defined as revenue generated from outsourced research and development services commissioned by pharmaceutical companies, including discovery, preclinical, clinical, quality control, diagnostics (CDx/Dx), and bioinformatics services.

DeciBio's Pharma R&D Services Market Report, First Edition: 2024-2029 is now available for purchase. Download a sample of the report here.

‍